CI Stock Analysis: Buy, Sell, or Hold?
CI - The Cigna Group
$258.08
-3.88 (-1.48%)
▼
5d:
-1.3%
30d:
-10.95%
90d:
-6.67%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 01, 2026
Smart Money Distribution
CI is up 3.4% this week, but smart money is buying puts. Top strike: $310 2026-04-17 with 1,816 OI. Put ratio: 69% View Scanner →
Strength: 3.6/10
Get Alerted When CI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CI trading at deep discount. Market pricing in -4.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: CI trading at deep discount. Market pricing in -4.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$409.62
Based on 7.1% avg growth
INTRINSIC VALUE TODAY
$254.34
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CI is currently trading at $258.08, which is considered oversold relative to its 30-day fair value range of $262.80 to $283.31. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.7) compared to its historical average (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 4.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $259.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $338.79 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $259.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $338.79 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$262.80 -
$283.31
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.3% below Wall St target ($338.79)
Fair Price Analysis
30-Day Fair Range
$262.80 -
$283.31
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$259.00
Resistance Level
$273.11
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.72
Wall Street Target
$338.79
(+31.3%)
Revenue Growth (YoY)
10.4%
Earnings Growth (YoY)
-9.3%
Profit Margin
2.2%
Valuation Discount vs History
-4.0% cheaper
PE vs Historical
7.7 vs 8.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.0%
(market-implied from PE analysis)
1-Year Target
$247.76
(-4%)
2-Year Target
$237.85
(-8%)
3-Year Target
$228.33
(-12%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$257.45
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.2%)
$1001.53
(+288%)
Base:
(SPY PE: 7.7, Growth: 10.2%)
$345.76
(+34%)
Bear:
(PE: 6.6, Growth: 10.2%)
$293.90
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 11.85 | Current EPS (TTM): $22.18
Bull Case
$436.46
(+67%)
Analyst growth 51.0%, PE expands to 13.0
Base Case
$396.78
(+52%)
Market implied 51.0%, PE stable at 11.9
Bear Case
$178.73
(-32%)
Severe decline -20.0%, PE contracts to 10.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.7 to 8.7
Stabilization Target:
$290.99
(+12.8%)
PE Expansion Potential:
+12.8%
Share & Embed Analysis
Last updated: March 30, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CI showing a specific setup today?
Insider Activity (6 Months)
7
Buys
7
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole S Jones
SELL
2307 shares
2026-03-02
Everett Neville
SELL
1719 shares
2026-03-02
Ro Khanna
BUY
2026-02-24
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$97 | 57 HOLD |
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$361 | 49 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$381 | 62 BUY |
|
HUM
Humana Inc |
HOLD
26 analysts |
$212 | 61 BUY |
|
CNC
Centene Corp |
BUY
19 analysts |
$43 | 45 HOLD |
Advanced CI Option Strategies
Professional options setups generated by AI based on today's CI price and gamma walls.
